Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II platform trial of feladilimab plus docetaxel versus docetaxel in relapsed/refractory advanced NSCLC
NL-OMON55684Phase 2Completed
- Sponsor
- GSK
- Start
- May 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Docetaxel monotherapy with Feladilimab plus docetaxel (2 arms). Primary endpoint: Overall survival. Started May 2019; status: completed.
02
Drugs
feladilimabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55684.